Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia

被引：6

作者：

Tam, Constantine S. ^{[1
,8
]}

Trotman, Judith ^{[2
,3
]}

Opat, Stephen ^{[4
,5
]}

Stern, Jennifer C. ^{[6
]}

Allewelt, Heather ^{[6
]}

By, Kunthel ^{[6
]}

Novotny, William ^{[6
]}

Huang, Jane ^{[6
]}

Tedeschi, Alessandra ^{[7
]}

机构：

[1] Monash Univ, Alfred Hosp, Melbourne, Vic, Australia

[2] Concord Repatriat Gen Hosp, Concord, NSW, Australia

[3] Univ Sydney, Concord, NSW, Australia

[4] Monash Hlth, Clayton, Vic, Australia

[5] Monash Univ, Clayton, Vic, Australia

[6] BeiGene, San Mateo, CA USA

[7] ASST Grande Osped Metropolitano Niguarda, Milan, Italy

[8] Alfred Hosp, 55 Commercial Rd, Melbourne, Vic, Australia

来源：

BLOOD ADVANCES | 2023年 / 7卷 / 12期

关键词：

D O I：

10.1182/bloodadvances.2022008990

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2884 / 2887

页数：4

共 50 条

[11] Interest of vemurafenib in relapsed or refractory hairy cell leukemia
Philippe, Laure
HEMATOLOGIE, 2015, 21 (06): : 321 - 322
[12] Rituximab-Vemurafenib Combination for the Treatment of Relapsed/Refractory Hairy Cell Leukemia
Sevindik, Omur
Gemici, Aliihsan
Mutlu, Yasa Gul
Aydin, Berrin Balik
Cakir, Asli
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S286 - S286
[13] Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia
Kreitman, Robert J.
Pastan, Ira
ONCOLOGIST, 2020, 25 (01): : E170 - E177
[14] Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?
Troussard, Xavier
Maitre, Elsa
Paillassa, Warne
BULLETIN DU CANCER, 2021, 108 (7-8) : 771 - 778
[15] Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Brown, J. R.
Eichhorst, B.
Hillmen, P.
Jurczak, W.
Kazmierczak, M.
Lamanna, N.
O'Brien, S. M.
Tam, C. S.
Qiu, L.
Zhou, K.
Simkovic, M.
Mayer, J.
Gillespie-Twardy, A.
Ferrajoli, A.
Ganly, P. S.
Weinkove, R.
Grosicki, S.
Mital, A.
Robak, T.
Osterborg, A.
Yimer, H. A.
Salmi, T.
Wang, M. -D. -Y.
Fu, L.
Li, J.
Wu, K.
Cohen, A.
Shadman, M.
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (04): : 319 - 332
[16] Moxetumomab Pasudotox Approved in Relapsed/Refractory Hairy Cell Leukemia
Schuyler, Devon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (10)
[17] Immunotoxins in the treatment of refractory hairy cell leukemia
Kreitman, Robert J.
Pastan, Ira
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2006, 20 (05) : 1137 - +
[18] BUDGET IMPACT OF ZANUBRUTINIB FOR TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES
Liu, S.
Yang, K.
Xiao, Y.
Gani, R.
Xue, M.
Tang, B.
VALUE IN HEALTH, 2022, 25 (12) : S65 - S66
[19] Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia
Kreitman, Robert J.
Arons, Evgeny
Stetler-Stevenson, Maryalice
Fitzgerald, David J. P.
Wilson, Wyndham H.
Pastan, Ira
LEUKEMIA & LYMPHOMA, 2011, 52 : 82 - 86
[20] Pilot study of rituximab in refractory or relapsed hairy cell leukemia (HCL).
Thomas, DA
O'Brien, S
Cortes, J
Giles, FJ
Koller, C
Estey, E
Kurzrock, R
Faderl, S
Pierce, S
Keating, MJ
Kantarjian, H
BLOOD, 1999, 94 (10) : 705A - 705A

← 1 2 3 4 5 →